<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874012</url>
  </required_header>
  <id_info>
    <org_study_id>20200559</org_study_id>
    <nct_id>NCT04874012</nct_id>
  </id_info>
  <brief_title>Effect of Taurine on Glycemic, Lipid and Inflammatory Profile in Individuals With Type 2 Diabetes</brief_title>
  <acronym>TAUGLIP-DM2</acronym>
  <official_title>Effect of Taurine on Glycemic, Lipid and Inflammatory Profile in Individuals With Type 2 Diabetes: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk&#xD;
      factor for comorbidities and death. Although conventional pharmacotherapy is effective, some&#xD;
      individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a&#xD;
      semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a&#xD;
      nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose&#xD;
      and cholesterol, but there are no well-conducted clinical studies evaluating the effect of&#xD;
      taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a&#xD;
      protective effect from diabetic nephropathy. The hypothesize of this study is that taurine&#xD;
      administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in&#xD;
      DM2 individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled clinical trial will be conducted at Hospital&#xD;
      de Clínicas de Porto Alegre (HCPA), Brazil. A total of 94 participants with DM2 will be&#xD;
      recruited and randomized on a 1:1 ratio to receive 3 g taurine as a powder for oral&#xD;
      suspension, twice per day, for 12 weeks or packets containing placebo. Blood will be&#xD;
      collected prior to the treatment and after 12 weeks for glycated hemoglobin, fasting glucose,&#xD;
      insulinemia, total cholesterol and fractions, triglycerides, C-reactive protein, creatinine,&#xD;
      urea, tumor necrosis factor-alpha (TNF-α), interleukin 1 and 6 (IL-1 and IL-6) measures.&#xD;
      Urine will be collected at baseline and after 12 weeks for creatine, protein, and albumin&#xD;
      measured. Anthropometric parameters and a 24-h dietary recall will be monthly investigated.&#xD;
      Fourteen days before the end of the trial, participants will be connected to a continuous&#xD;
      glucose monitoring system for glucose monitoring system for glucose variability evaluation.&#xD;
      Participants will be contacted by phone weekly to report adverse effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The generation of the sequence of numbers will be done by a blinded researcher, after selecting the participant by the inclusion and exclusion criteria. The concealment of allocation will be implemented by a central randomization routine, conducted by researchers with access to the list and by the researcher responsible for requesting the code for placement of individuals in the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Changes from baseline glycated hemoglobin levels at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Changes from baseline fasting glucose levels at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin levels</measure>
    <time_frame>baseline and12 weeks</time_frame>
    <description>Changes from baseline insulin levels at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum cholesterol (CT) and fractions</measure>
    <time_frame>baseline and12 weeks</time_frame>
    <description>Changes from baseline total serum cholesterol, high-density lipoprotein (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides serum levels</measure>
    <time_frame>baseline and12 weeks</time_frame>
    <description>Changes from baseline triglycerides serum levels at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>for 2 weeks (10-12th week)</time_frame>
    <description>Changes in glucose levels throughout the day assessed by a continuous glucose monitoring system (CGMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Changes from baseline TNF-α, IL-1, IL-6 levels at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein creatine index</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Changes from baseline protein creatinine index measured in urine at 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Changes from baseline albuminuria levels at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>baseline and 4, 8, and 12 weeks</time_frame>
    <description>Changes from baseline BMI calculated by weight (kg) and height (cm) at 4, 8, and 12 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants into the placebo group will receive the same treatment regimen, but with packets of the same appearance and size containing only vehicle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taurine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 6 gy taurine divided into twice/day orally administration for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator Taurine</intervention_name>
    <description>Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.</description>
    <arm_group_label>Taurine</arm_group_label>
    <other_name>Taurine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Female and male individuals, with clinical diagnosis of DM2 for at least 6 months;&#xD;
&#xD;
          -  Age over 30 years;&#xD;
&#xD;
          -  BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months;&#xD;
&#xD;
          -  HbA1c between 7.5% and 10.5%.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Use of herbal supplements, antioxidants, and multivitamins in the last 3 months;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Chronic renal failure with glomerular filtration rate calculated by MDRD &lt; 30 mL/h;&#xD;
&#xD;
          -  Myocardial infarction in the last than 6 months&#xD;
&#xD;
          -  Current neoplasia;&#xD;
&#xD;
          -  Chronic use of glucocorticoids;&#xD;
&#xD;
          -  Bariatric surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatriz D'agord Schaan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beatriz D'agord Schaan</last_name>
    <phone>55 51 3359-8000</phone>
    <email>bschaan@hcpa.edu.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monique Vargas Cardoso</last_name>
    <phone>55 51 992757732</phone>
    <email>moniquevargas85@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clínicas</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Beatriz D'agord Schaan</last_name>
      <phone>55 51 3359-8000</phone>
      <email>bschaan@hcpa.edu.br</email>
    </contact>
    <contact_backup>
      <last_name>Monique Eva Vargas Cardoso</last_name>
      <phone>55 51 992757732</phone>
      <email>moniquevargas85@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Caletti G, Herrmann AP, Pulcinelli RR, Steffens L, Morás AM, Vianna P, Chies JAB, Moura DJ, Barros HMT, Gomez R. Taurine counteracts the neurotoxic effects of streptozotocin-induced diabetes in rats. Amino Acids. 2018 Jan;50(1):95-104. doi: 10.1007/s00726-017-2495-1. Epub 2017 Sep 21.</citation>
    <PMID>28936709</PMID>
  </reference>
  <reference>
    <citation>Caletti G, Olguins DB, Pedrollo EF, Barros HM, Gomez R. Antidepressant effect of taurine in diabetic rats. Amino Acids. 2012 Oct;43(4):1525-33.</citation>
    <PMID>22302366</PMID>
  </reference>
  <reference>
    <citation>Chauncey KB, Tenner TE Jr, Lombardini JB, Jones BG, Brooks ML, Warner RD, Davis RL, Ragain RM. The effect of taurine supplementation on patients with type 2 diabetes mellitus. Adv Exp Med Biol. 2003;526:91-6.</citation>
    <PMID>12908588</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.</citation>
    <PMID>23295957</PMID>
  </reference>
  <reference>
    <citation>Fukuda N, Yoshitama A, Sugita S, Fujita M, Murakami S. Dietary taurine reduces hepatic secretion of cholesteryl ester and enhances fatty acid oxidation in rats fed a high-cholesterol diet. J Nutr Sci Vitaminol (Tokyo). 2011;57(2):144-9.</citation>
    <PMID>21697633</PMID>
  </reference>
  <reference>
    <citation>Gomez R, Caletti G, Arbo BD, Hoefel AL, Schneider R Jr, Hansen AW, Pulcinelli RR, Freese L, Bandiera S, Kucharski LC, Barros HMT. Acute intraperitoneal administration of taurine decreases the glycemia and reduces food intake in type 1 diabetic rats. Biomed Pharmacother. 2018 Jul;103:1028-1034. doi: 10.1016/j.biopha.2018.04.131. Epub 2018 Apr 25.</citation>
    <PMID>29710660</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84. doi: 10.2337/dc21-S006. Review.</citation>
    <PMID>33298417</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S53-S72. doi: 10.2337/dc21-S005. Review.</citation>
    <PMID>33298416</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>taurine</keyword>
  <keyword>inflammation</keyword>
  <keyword>glucose metabolism disorders</keyword>
  <keyword>glycated hemoglobin</keyword>
  <keyword>diabetes mellitus, type 2</keyword>
  <keyword>amino acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

